Effectiveness of a Controlled 5-FU Delivery Based on FZD10 Antibody-Conjugated Liposomes in Colorectal Cancer In vitro Models
Open Access
- 10 July 2020
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (7), 650
- https://doi.org/10.3390/pharmaceutics12070650
Abstract
The use of controlled delivery therapy in colorectal cancer (CRC) reduces toxicity and side effects. Recently, we have suggested that the Frizzled 10 (FZD10) protein, a cell surface receptor belonging to the FZD protein family that is overexpressed in CRC cells, is a novel candidate for targeting and treatment of CRC. Here, the anticancer effect of novel immuno-liposomes loaded with 5-Fluorouracil (5-FU), decorated with an antibody against FZD10 (anti-FZD10/5-FU/LPs), was evaluated in vitro on two different CRC cell lines, namely metastatic CoLo-205 and nonmetastatic CaCo-2 cells, that were found to overexpress FZD10. The anti-FZD10/5-FU/LPs obtained were extensively characterized and their preclinical therapeutic efficacy was evaluated with the MTS cell proliferation assay based on reduction of tetrazolium compound, scratch test, Field Emission Scanning Electron Microscopes (FE-SEM) investigation and immunofluorescence analysis. The results highlighted that the cytotoxic activity of 5-FU was enhanced when encapsulated in the anti-FZD10 /5-FU/LPs at the lowest tested concentrations, as compared to the free 5-FU counterparts. The immuno-liposomes proposed herein possess a great potential for selective treatment of CRC because, in future clinical applications, they can be encapsulated in gastro-resistant capsules or suppositories for oral or rectal delivery, thereby successfully reaching the intestinal tract in a minimally invasive manner.This publication has 56 references indexed in Scilit:
- Clinical Significance of Frizzled Homolog 3 Protein in Colorectal Cancer PatientsPLOS ONE, 2013
- Strategies to Prevent and Treat Cardiovascular Risk in Cancer PatientsSeminars in Oncology, 2013
- Vimentin in cancer and its potential as a molecular target for cancer therapyCellular and Molecular Life Sciences, 2011
- Development of a liposomal nanoparticle formulation of 5-Fluorouracil for parenteral administration: Formulation design, pharmacokinetics and efficacyJournal of Controlled Release, 2011
- Nanoparticle therapeutics: an emerging treatment modality for cancerNature Reviews Drug Discovery, 2008
- 5-Fluorouracil: Mechanisms of Resistance and Reversal StrategiesMolecules, 2008
- Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitroNature Protocols, 2007
- REDUCED ANTIOXIDANT DEFENSE CAPACITY IN MYOCARDIAL TISSUE FROM GUINEA PIGS TREATED WITH 5-FLUOROURACILJournal of Toxicology and Environmental Health, Part A, 2000
- Different Intravenous Administration Techniques for 5-Fluorouracil Pharmacokinetics and Pharmacodynamic EffectsActa Oncologica, 1996